Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Botensilimab ± Balstilimab in Patients with Advanced Cutaneous Melanoma Refractory/Resistant to Anti–PD-(L)1 ± CTLA-4: A Phase 2 Trial
May 31, 2026
,
Atkins, M. et al.
ASCO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti–CTLA-4 antibody) plus balstilimab (anti–PD-1 antibody) in patients with treatment-refractory ovarian cancer
Other Articles & Publications
Journal for ImmunoTherapy of Cancer (JITC)
December 23, 2025
,
Porter, et al.
Balstilimab (PD-1 inhibitor)
Zalifrelimab (CTLA-4 Antagonist)
Efficacy and safety of balstilimab with or without zalfrelimab in recurrent cervical cancer: Results from the global phase 2 RaPiDs trial (GOG-3028)
ESMO
European Society for Medical Oncology (ESMO)
October 18, 2025
,
O’Malley, et al.
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti-CTLA-4)
Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
ESMO
European Society for Medical Oncology (ESMO)
October 17, 2025
,
Gordon et al.